

1 **Immunogenicity and adverse events**  
2 **of priming with inactivated whole SARS-CoV-2 vaccine (CoronaVac)**  
3 **followed by boosting the ChAdOx1 nCoV-19 vaccine**

4  
5 Surakameth Mahasirimongkol<sup>1\*</sup>, Athiwat Khunphon<sup>1</sup>, Oraya Kwangsukstid<sup>3</sup>  
6 Sompong Sapsutthipas<sup>2</sup>, Minkwan Wichaidit<sup>3</sup>, Archawin Rojanawiwat<sup>5</sup>  
7 Nuanjun Wichuckchinda<sup>1</sup>, Wiroj Puangtubtim<sup>1</sup>, Waranluk Pimpapai<sup>1</sup>  
8 Sakulrat Soonthorncharttrawat<sup>1</sup>, Asawin Wanitchang<sup>6</sup>  
9 Anan Jongkaewwattana<sup>6</sup>, Kanjana Srisutthisamphan<sup>6</sup>, Daraka Phainupong<sup>3</sup>  
10 Penpitcha Thawong<sup>1</sup>, Pundharika Piboonsiri<sup>1</sup>, Warittha Sawaengdee<sup>1</sup>  
11 Thitiporn Somporn<sup>2</sup>, Kanokphon Ritthitham<sup>2</sup>, Supaporn Chumpol<sup>2</sup>  
12 Nadthanan Pinyosukhee<sup>1</sup>, Rattanawadee Wichajarn<sup>1</sup>  
13 Panadda Dhepaksorn<sup>1</sup>, Sopon Iamsiritahworn<sup>4</sup>, Supaporn Phumiamorn<sup>2</sup>

14

15 **Affiliations:**

16 <sup>1</sup>Medical Life Sciences Institute, Department of Medical Sciences,  
17 Nonthaburi, Thailand.

18 <sup>2</sup>Institute of Biological Products, Department of Medical Sciences  
19 Nonthaburi, Thailand.

20 <sup>3</sup>Institute of Dermatology, Department of Medical Service, Nonthaburi,  
21 Thailand

22 <sup>4</sup>Division of epidemiology, Department of disease control, Nonthaburi, Thailand

23 <sup>5</sup>National Institute of Health, Nonthaburi, Thailand

24 <sup>6</sup>Virology and Cell technology Research Team, National Center for Genetic  
25 Engineering and Biotechnology(BIOTEC), National Science and Technology  
26 Development Agency (NSTDA), Pathumthani, Thailand

27

28

29

30 **Corresponding Author:** Surakameth Mahasirimongkol, MD, Ph.D.

31 Medical Life Sciences Institute, Department of Medical Sciences, Ministry of  
32 Public Health

33 88/7 Tivanond Road ,Nonthaburi 11000, Thailand

34 Tel: (+66) 2951000 ,0-2589-9580-8; Fax: (+66) 2-591-1707

35 E-mail: Surakameth.m@dmsc.mail.go.th

36

37

38

39

40

41

42

43

44

45

46 **Abstract**

47 **Background:** Responding to SARS-CoV-2 Delta variants escaped the vaccine-  
48 induced immunity and waning immunity from the inactivated whole virus  
49 vaccine, Thailand recently proposed a heterologous inactivated whole virus  
50 vaccine (CoronaVac) viral vector vaccine (ChAdOx1 nCoV-19) prime-boost  
51 vaccine regimen(I/V). This study aims to evaluate the immunogenicity and  
52 adverse events of this regimen by comparison with homologous CoronaVac,  
53 ChAdOx1 nCoV-19, and convalescent serum.

54 **Method:** Immunogenicity was evaluated by the level of IgG antibodies against  
55 the receptor-binding domain of the SARS-CoV-2 spike protein (S1 subunit)  
56 (anti-S RBD). At 2 weeks following the second dosage, a selection of random  
57 samples was tested for plaque reduction neutralisation (PRNT) and Pseudotype-  
58 Based Microneutralization test (PVNT) against SARS-CoV-2 variants of  
59 concern (VOCs). The safety profile of heterologous CoronaVac-ChAdOx1  
60 nCoV-19 prime-boost vaccine regimen was described by interviewing at the 1-  
61 month visit.

62 **Result:** Between April to August 2021,426 participants were included in the  
63 study, with 155 obtaining CoronaVac-ChAdOx1 nCoV-19(I/V),32 obtaining  
64 homologous CoronaVac(I/I),47 obtaining homologous ChAdOx1 nCoV-19(V/V),169  
65 with history covid-19 infection. Geometric mean titers (GMTs) of anti-S RBD  
66 level in the I/V group compare 2wks and 4 wks ( 873.9 vs 639,p=0.00114).At

67 4 wks, GMTs of anti-S RBD level in I/V group was 639, 95% CI 63-726, and  
68 natural infection group 177.3, 95% CI 42-221, and V/V group 211.1, 95%  
69 CI 77-152, and I/I group 108.2, 95% CI 77-152; all  $p < 0.001$ ). At 2 wks, The  
70 GMTs of 50%PRNT of 19 sampling from the I/V group is 434.5, 95% CI  
71 326-579, against wild type and 80.4, 95% CI 56-115, against alpha and 67.4,  
72 95% CI 48-95, against delta and 19.8, 95% CI 14-30, against beta; all  $p < 0.001$ .  
73 At 2 wks, The GMTs of 50%PVNT of 15 sampling from the I/V group is 597.8,  
74 95% CI 368-970, against wild type and 163.9, 95% CI 89-301, against alpha  
75 and 157.7, 95% CI 66-378, against delta. The AEs in the I/V schedule were  
76 well tolerated and generally unremarkable.

77 **Conclusion:** The I/V vaccination is a mixed regimen that induced higher  
78 immunogenicity and shall be considered for responding to Delta Variants when  
79 only inactivated whole virus vaccine and viral vector vaccine was available.

80

81

82

83

84

85

86

87

88

## 89 **Background**

90 In lower and middle-income countries, where the access to the COVID-19  
91 vaccine is limited in 2021, the estimated total COVID19 vaccine in 2021 is 4  
92 billion doses while the demand is around 8 billion doses. Lower and middle-  
93 income countries relied on the COVID-19 vaccine such as the inactivated whole  
94 virus vaccine, CoronaVac<sup>1</sup> (Sinovac Biotech, Beijing, China), and viral vector  
95 vaccine such as ChAdOx1 nCOV-19 vaccine<sup>2</sup>.

96 The heterologous prime-boost vaccination has been reported to be induced  
97 higher immunogenicity for various vaccine<sup>3</sup> and routinely practice in the annual  
98 vaccination program such as influenza, or in the vaccination program, where  
99 vaccination of different manufacturing platforms is considered replaceable.

100 While only one covid vaccine was designed based on heterologous rAd26 and  
101 rAd5 vector-based COVID-19 vaccination, which enables a high level of  
102 immunogenicity<sup>4</sup>. Most of the vaccines were not utilized the heterologous  
103 vaccination concept because most manufacturers did not develop the vaccine  
104 from two different vaccine delivery platforms or manufacturing platforms. It is  
105 a generally higher cost for manufacturing vaccines with two manufacturing  
106 platforms. The outbreaks of Delta variants from the beginning of 2021 in India  
107 are devastating with estimates of 10 times higher number of deaths than the  
108 reported deaths due to its higher transmissibility, more severe and vaccine  
109 escape capability<sup>5</sup>. Based on these characteristics, the Delta variant was  
110 recognized as the variants of concerns (VOCs) by Public Health England, US

111 Center for Disease Control, and World Health Organization (WHO). WHO  
112 issued global notices of Delta variant as the dominant variants and notification  
113 of the vaccination program to accelerate the implementation of any vaccine that  
114 is readily accessible. The outbreaks of the Delta variant in Indonesia occurred in  
115 the middle of 2021<sup>6</sup>. In July 2021, the Royal Society of Physicians in Indonesia  
116 reported the highest mortality rates from COVID19 in health care workers who  
117 were fully vaccinated with CoronaVac, this report<sup>6</sup> prompted global concerns  
118 about the efficacy of inactivated viral vaccine against the Delta variants after  
119 several months post-vaccination. In some countries where the inactivated viral  
120 vaccine was used at the beginning of 2021, such as Bahrain, China, United  
121 Arab Emirates, and Egypt, the booster dose (third dose) by mRNA vaccine  
122 were offered to elderly and high-risk populations in the middle of 2021<sup>7</sup> The  
123 immunogenicity study of inactivated whole virus vaccine in Thailand suggested  
124 that inactivated virus vaccine with Wuhan's variant S protein provided low  
125 immunogenicity against the alpha and Delta variant<sup>8</sup>. The Delta variant in  
126 Thailand was first detected in May 2021, from the construction workers site in  
127 the Laksi district of Bangkok, where workers from Myanmar and Cambodia  
128 worked with Thai nationals. Within 3 months duration, and multiple outbreaks  
129 of the Delta variant, it took over the Alpha variant which predominated in  
130 Bangkok from April to May, and became the dominant variants of COVID19 in  
131 Thailand in the first week of August 2021. Like other countries in Southeast  
132 Asia, Thailand began the COVID-19 vaccination program with CoronaVac and

133 ChAdOx1 nCoV-19, viral vector vaccine from AstraZeneca, mainly due to the  
134 accessibility of the inactivated viral vaccine from China. While the vaccination  
135 program was implemented from March to May 2021, a group of individuals  
136 who experienced vaccine-induced adverse reactions from CoronaVac was  
137 offered the ChAdOx1 nCoV-19 as the only possible alternative to CoronaVac,  
138 and their immunogenicity was measured and reported<sup>9</sup>. Based on  
139 immunogenicity data in those who experienced AEs from CoronaVac, a  
140 heterologous vaccine schedule, priming with inactivated SARS-CoV-2 vaccine  
141 and followed with viral vector vaccine were proposed and adopted based on the  
142 neutralizing antibody data from this vaccine schedule by the national  
143 vaccination program on 12<sup>th</sup> July 2021. Therefore, Thailand proposed the  
144 heterologous prime-boost regimen, a 21-day interval between the first dose  
145 inactivated whole virus vaccine (CoronaVac) and the second dose viral vector  
146 vaccine (ChAdOx1 nCoV-19 vaccine), from now we called this the “I/V”  
147 regimen, the only regimen that available as the preferred schedule along with  
148 the existing vaccine schedule for mitigating the mortality of COVID19  
149 pandemic in Thailand. However, the immunogenicity in a larger number of  
150 samples and detailed information of common reactogenicity especially the  
151 adverse reaction of the second vaccination dose of ChAdOx1 nCoV-19 after  
152 inactivated viral vaccine had never been reported. Here we aim to determine  
153 the immunogenicity two weeks and four weeks after vaccination with the I/V

154 schedule and describe the common adverse drug reactions from this I/V  
155 schedule.

## 156 **Method**

157 **Study design.** In this observational study, two groups of healthy individuals  
158 without a known history of covid-19 infection or exposure were recruited in this  
159 study. Their covid-19 infection or exposure were verified by interviewing and  
160 re-checking with the national registry of COVID-19. In I/V group was divided  
161 into two subgroups 1a and 1b. First, Group 1a, 30 participants, who received  
162 CoronaVac were those who experienced at least an adverse event following  
163 immunization and health care providers recommended that their second covid-  
164 19 vaccine should be switched to ChAdOx1 nCoV-19. Within the first half of  
165 2021, only ChAdOx1 nCoV-19 is available in Thailand as the alternative to the  
166 inactivated viral vaccine. These patients were recruited from  
167 the Bangsue central vaccination center, the largest center for COVID-19  
168 vaccination in Thailand. The group 1b of participants were enrolled  
169 from MOPH vaccination center vaccination site at the permanent secretary  
170 office of the Ministry of Public health, those who were scheduled to receive a  
171 second dose of inactivated viral vaccine were offered to switch their second  
172 dose vaccination to ChAdOx1 nCoV-19. The offer is based on the  
173 recommendation to I/V vaccination from the national vaccination academic  
174 subcommittee. The benefit of this I/V regimen was an opportunity to achieve



175 higher immunogenicity than I/I regimens and in shorter duration intervals when  
176 compared to the V/V regimen, the risk was the possibility of a higher rate of  
177 adverse events than the I/I schedule.

178 The benefit and risks of second vaccination with ChAdOx1 nCoV-19 were  
179 explained to participants. The ethical approval of this study was approved by  
180 the ethical committee of the Department of Medical Sciences with approval  
181 number; MOPH 0625/EC060. Written informed consent was obtained from all  
182 participants.

183 Vaccination was performed according to the vaccination center guideline; the  
184 timing and lot of vaccines were recorded in the national vaccine information  
185 system called “Ministry of Public Health Vaccine Information Center (MOPH-  
186 IC)”. Immunogenicity analysis after the secondary vaccination at  
187 the Bangsue central vaccination center (BCVC) was offered as the test-based  
188 voluntarily. All participants provided written informed consent to have their  
189 immunogenicity and the adverse event included in this study.-

190 All participants were invited to monitor immunogenicity at 2 weeks and 4  
191 weeks after the second vaccination with ChAdOx1 nCoV-19.

192 The immunogenicity data from the fully vaccinated viral vector vaccine (V/V  
193 group) were retrieved from participants at BCVC.

194 The fully vaccinated inactivated virus vaccine (I/I group) was recruited from  
195 another vaccine study in DMSc. The convalescent serum from those with

196 COVID-19 Delta variant infection from Laksi district was utilized for  
197 immunogenicity analysis on Natural infection in 2021 (NI group). Written  
198 informed consent was acquired from these two groups of fully vaccinated  
199 individuals and one group of natural infection 2021. The timing of samples  
200 collected from I/I groups and V/V groups was at 4 weeks after vaccination.

201

### 202 **Quantification of SARS-CoV-2 anti-S RBD antibody**

203 The level of immunoglobulin class G (IgG) antibodies to the receptor-binding  
204 domain (RBD) of S1 subunit spike protein of SARS-CoV-2 was measured and  
205 quantified in human serum or plasma by using the ARCHITECT System  
206 (Abbott, Abbott Park, Illinois, USA) chemiluminescent microparticle  
207 immunoassay (CMIA) (SARS-CoV-2 IgG II Quant, Abbott Ireland, Sligo,  
208 Ireland) with measuring reportable range from 6.8 Abbott Arbitrary Unit  
209 (AU/mL) to 80,000.0 AU/mL (up to 40,000 AU/mL with onboard 1:2 dilution).  
210 Values higher than 50 AU/mL were considered positive. Based on the evaluated  
211 dilutions of the World Health Organization (WHO) International Standard  
212 (NIBSC Code 20-136) for anti-SARS-CoV-2 human immunoglobulin in WHO  
213 binding antibody unit (WHO BAU/mL) with the SARS-CoV-2 IgG II  
214 Quant assay with Abbott internal reference calibrators, the correlation between  
215 relationships of the AU/mL unit to the WHO (BAU/mL unit is at  $0.142 \times$   
216 AU/mL) with the 0.999 correlation coefficient.

## 217 **Pseudotype-Based Microneutralization Assay against SARS-CoV-2**

218 Pseudotype-Based Microneutralization Assay was carried out at the viral  
219 vaccine research center, National center for sciences and technology  
220 (NSTDA). Pseudotyped viruses (PVs) were produced in HEK293T/17 cells.  
221 HEK293T/17 producer cells were sub-cultured in 6-well plates (Thermo Fisher  
222 Scientific, Waltham, MA, USA) and co-transfected at 80-90% confluence with  
223 the p8.91 lentiviral packaging plasmid (500 ng), the pCSFLW firefly luciferase  
224 reporter plasmid (1  $\mu$ g), and the pCAGGS plasmid encoding codon-optimized  
225 SARS-CoV-2 spike (1.5 $\mu$ g)<sup>10</sup>. The transfection was performed  
226 using polyethylenimine (PEI). The cell supernatants were collected 72 h before  
227 storage in microcentrifuge tubes at  $-80$  °C.

228 Pseudotype-based microneutralization (pMN) assays were performed as  
229 previously described<sup>10</sup> with some modifications. Briefly, human sera from  
230 SARS-CoV-2 seropositive and seronegative were subjected to two-fold dilution  
231 (starting from 1:40) in a white flat-bottom 96-well tissue culture-treated plate,  
232 and 50  $\mu$ L of PV containing supernatant diluted in complete DMEM to give  $5 \times$   
233  $10^5$  RLU equivalent was added per well. The plate was then centrifuged at  $300 \times$   
234 g for 3 min before incubation in a humidified cell-culture incubator for 1 h at 37  
235 °C, 5% CO<sub>2</sub>. Subsequently, HEK293T cells stably expressing human ACE2 and  
236 TMPRSS2 ( $1.5 \times 10^4$  cells/well) were mixed with the PV-serum complex before  
237 incubation in a humidified cell-culture incubator for 48 h at 37 °C in 5% CO<sub>2</sub>.  
238 To measure luminescence activity, equal volumes of Bright-

239 Glo™ reagent (Promega, Madison, WI, USA) and Phosphate Buffered Saline  
240 (PBS) were mixed and 25 µL added to each well; luminescence output was  
241 measured using a Synergy™ HTX Multi-Mode Microplate Reader (BioTek,  
242 Winooski, VT, USA) after 5 min incubation at room temperature. Analysis was  
243 performed by non-linear regression after normalization to 100% and 0%  
244 neutralization using GraphPad Prism Software.

245

### 246 **Plaque Reduction Neutralization Test (PRNT)**

247 PRNT in this study is developed and tested by the Institute of Biological  
248 Products, WHO- contracted laboratory at the Department of Medical  
249 Sciences. Vero cells were seeded at  $2 \times 10^5$  cells/well/ 3 ml and placed in 37°C,  
250 5% CO<sub>2</sub> incubator for 1 day. Test serum was initially diluted at 1:10, 1:40,  
251 1:160, and 1:640, respectively. The SARS-CoV-2 virus was diluted in a culture  
252 medium to yield 40-120 plaques/well in the virus control wells. Cell control  
253 wells, convalescent patient serum, and normal human serum were also included  
254 as assay controls. The neutralization was performed by mixing the equal volume  
255 of diluted serum and the optimal plaque numbers of SARS CoV-2 virus at 37°C  
256 in the water bath for 1 hr. After removing the culture medium from Vero cell  
257 culture plates, 200 ul of the virus-serum antibody mixture were inoculated into  
258 monolayer cells and then rocked the culture plates every 15 min for 1 h. Three  
259 ml of overlay semisolid medium (containing 1% of carboxymethylcellulose,  
260 Sigma Aldrich, USA, with 1% of 10,000 units/ml Penicillin-10,000 ug/ml

261 Streptomycin (Sigma, USA) and 10% FBS) were replaced after removing  
262 excessive viruses. All plates were incubated at 37OC, 5% CO2 for 7 days. Cells  
263 were fixed with 10% (v/v) formaldehyde then stained with 0.5% crystal violet  
264 in PBS. The number of plaques formed was counted in triplicate wells and the  
265 percentage of plaque reduction at 50% (PRNT50) was calculated. The PRNT50  
266 titer of the test sample is defined as the reciprocal of the highest test serum  
267 dilution for which the virus infectivity is reduced by 50% when compared with  
268 the average plaque counts of the virus control and was calculated by using a  
269 four-point linear regression method. Plaque counts for all serial dilutions of  
270 serum were scored to ensure that there was a dose-response.

### 271 **Monitoring of adverse events after vaccination**

272 Adverse events (AEs) were determined according to the SOP 43-05-17-CL-006  
273 Handling and reporting of Adverse Events protocol, AEs were retrieved from  
274 questionnaires and/or telephone-based interviews. The registered nurse  
275 contacted all subjects, and none of them reported any serious adverse  
276 effects. The rates of each adverse drug reaction were reported. The Common  
277 Terminology Criteria for Adverse Events - Version 5.0 used to evaluate the  
278 severity of AEs.

279

280

281

## 282 **Statistical analysis**

283 All the statistical analyses were performed using R (version 4.0.2)<sup>11</sup> and  
284 Rstudio (version 1.3.1093)<sup>12</sup>. The anti-SARS-CoV-2 RBD IgG level, PRNT<sub>50</sub>  
285 titer, and PVNT<sub>50</sub> titer were presented as geometric mean titers (GMTs) with 95  
286 percent confidence intervals (CI). The difference of the antibody levels between  
287 vaccine groups: NI, I/I, I/V, V/V, at 4 weeks with between 2 weeks and 4 weeks  
288 after having the I/V schedule were tested using the non-parametric (The Mann–  
289 Whitney U test)<sup>13</sup> (available within the R package rstatix). The Wilcoxon  
290 signed-rank test, a non-parametric statistical hypothesis test for paired data<sup>13</sup>,  
291 was applied to compare the PRNT<sub>50</sub> titers and PVNT<sub>50</sub> titers among selected  
292 SARS-CoV-2 variants. The Spearman's rank correlation coefficient<sup>11</sup> (R  
293 function cor. test) was used to assess how well the relationship between SARS-  
294 CoV-2 variants and neutralization Assays: PVNT<sub>50</sub> and PRNT<sub>50</sub>.

## 295 **Results**

296 Between April to August 2021, 403 participants were included in the study, with  
297 155 obtaining CoronaVac-ChAdOx1 nCoV-19 (I/V group), 32 obtaining  
298 homologous CoronaVac (I/I group), 47 obtaining homologous ChAdOx1 nCoV-  
299 19 (V/V group), 169 with history covid-19 infection (NI group) (figure 1,2). In I/V  
300 group, 155 participants were 76 (49.3%) male and 79 (50.97%) female. The  
301 median age was 40 years (SD 9.4), 124 (80%) participants in 18–49 years and  
302 31 (20%) of participants are in 50–70 years.

303 The Demographic data between vaccination groups were described in Table 1.

304

305 **Immunogenicity profiles of I/V schedule compared with other vaccine**  
306 **schedules in Thailand**

307 At 2wks visits, 149 participants were in the I/V group;6 participants missed  
308 their 2 wks visit but returned for visit at 4 weeks; geometric mean titers (GMTs)  
309 of anti-S RBD levels were at 873.9 BAU/mL (95% CI 768.4-993.8).

310 At 4 wks visit, 137 participants in I/V group, excluded 18 participants;  
311 1 participant excluded due to HIV and low CD4 count, 2 participants infected  
312 with covid 19 after 2 weeks visit and 15 participants were lost to follow up;  
313 GMTs of anti-S RBD levels were at 639 BAU/ml (95% CI 63-726).

314 At 4 wks after the 3-6 weeks (mean 3.5 wks) interval between the two-dose  
315 CoronaVac, 32 participants with GMTs of anti-S RBD levels were 108.2  
316 BAU/mL( 95% CI 77-152).

317 At 4 wks after the 8-12 weeks interval between the two-dose  
318 ChAdOx1 nCoV-19, 47 participants with GMTs of anti-S RBD  
319 levels were at 211.1 BAU/mL (95% CI 162-249).

320 For the natural infection group, 169 participants with documented covid 19  
321 infection from Laksi district with GMTs of anti-S RBD levels were  
322 177.3 BAU/ml (95% CI 42-221). Most of the natural infection groups are  
323 asymptomatic individuals.

324 At 4 wks following the I/V schedule provided significantly higher GMTs of  
325 anti-S RBD level when compared with I/I, V/V schedule, and natural infection  
326 group( $p<0.001$ ).

327

### 328 **Antibody levels at 2 weeks after second vaccination compared with 4 weeks**

329 -The antibody levels of the I/V schedule at 2 wks are significantly ( $p=0.00114$ )  
330 (873.9 BAU/mL, 95% CI 768.4-993.8) higher than the I/V schedule at 4 wks  
331 (639 BAU/mL, 95% CI 63-726). (Figure 4)

332 - The antibody levels of I/V schedule at 4 wks after second vaccination  
333 is significantly ( $p<0.001$ ) (639 BAU/mL, 95% CI 63-726) higher than the  
334 V/V group (211.1 BAU/mL, 95% CI 162-249), NI group (177.3 BAU/mL, 95%  
335 CI 42-221), I/I group (108.2 BAU/mL, 95% CI 77-152). (Figure 3)

336 An exceptional participant with undetectable antibody was characterized for the  
337 low level of the Binding Antibody Unit at 2.4 AU/mL, due to high-risk  
338 occupation from the interview, the participant was subsequently counseled for  
339 the HIV screening and tested positive with an anti-HIV rapid screening test (SD  
340 BIOINE HIV1/2 3.0, Standard Diagnostics, Kyonggi-Do, South Korea) and the  
341 CD4 level, at 6.8 %. This patient was then referred to confirmatory diagnosis  
342 and treatment of HIV. This participant was excluded from further analysis.



### 343 **COVID19 breakthrough infection following immunization**

344 During a telephone interview, two participants reported to the investigator that  
345 they couldn't attend the 4 wks visit for blood samples collection due to their  
346 COVID19 situation that they experienced during the third week after the I/V  
347 schedule. These two participants in the age range 30-35 are living in the same  
348 household. BAU data at 2 weeks were as followed: the first participant  
349 had 380.3 BAU/ml whereas the second participant had 1,145.7 BAU/ml. The  
350 two participants were confirmed with COVID19 infection by RT-PCR at a  
351 private hospital, the first participant was diagnosed with COVID19 3 days  
352 earlier than the second participant and both of them experienced mild  
353 symptomatic covid 19 (with fever, malaise, and headache).  
354 Their physician treated them with favipiravir, an antiviral agent, under a home  
355 isolation scheme, followed up chest radiography was unremarkable and reported  
356 no further complication.

357

### 358 **Neutralization antibody to variants of concern**

359 The PRNT<sub>50</sub> of 19 samples from the I/V schedule was analyzed and reported in  
360 figure 5 and table 7. While all 19 samples demonstrated the neutralizing activity  
361 against the Alpha and Delta variant at > 10 IC cut-off, the neutralizing activity to  
362 Beta variants was achieved in 63% of these samples. In 19 participants from the  
363 I/V group were evaluated for their neutralizing antibody (Nab) by PRNT<sub>50</sub> for

364 4 variants of SARS-CoV-2 (Wuhan-strain or wild type, Alpha variant, Delta  
365 variant, Beta variant). At 2 wks, the PRNT<sub>50</sub> was the highest against wild  
366 type (434.5 BAU/mL, 95% CI 326-579), that significantly higher than to Alpha  
367 variant (80.4 BAU/mL, 95% CI 56-115), Delta variant (67.4 BAU/mL, 95% CI 48-  
368 95) and Beta variant (19.8 BAU/mL, 95% CI 14-30), respectively ( $p < 0.001$ ).

369 Moreover, their PRNT<sub>50</sub> had the correlation coefficient with Ab to anti-s RBD  
370 level with wild type ( $\rho = 0.82$ ,  $p < 0.001$ ), alpha variant  
371 ( $\rho = 0.66$ ,  $p = 0.0027$ ), and Beta variant ( $\rho = 0.074$ ,  $p = 0.76$ ), delta variant  
372 ( $\rho = 0.17$ ,  $p = 0.48$ ) (Figure 7).

373 In addition, all participants ( $n = 19/19$ ) had PRNT<sub>50</sub> titers  $\geq 10$   
374 (Nab positivity cut-off)  $\geq 10$  (Nab positivity cut-off) against wild type, Alpha, and  
375 Delta strains. Participants ( $n = 12/19$ , 63%) had PRNT<sub>50</sub> titers  $\geq 10$  against beta  
376 variant (Table 9).

377

378

### 379 **Pseudo Neutralization antibody to variants of concern (PVNT)**

380 The PVNT<sub>50</sub> of 15 samples from the I/V schedule was analyzed and reported in  
381 figure 6 and table 8. From the I/V group, 15 participants were evaluated for  
382 their neutralizing antibody (Nab) by PVNT<sub>50</sub> for 3 variants of SARS-CoV-  
383 2 (wild type, Alpha variant, Delta variant). Beta variant for PVNT<sub>50</sub> was not  
384 available at the time of this study. At 2 wks, the GMTs of PVNT<sub>50</sub> is the highest

385 against wild type (597.8, 95% CI 368-970) that significantly ( $p < 0.001$ )  
386 greater than Alpha variant (163.9, 95% CI 89-301) and delta variant (157.7,  
387 95% CI 66-378) ( $p < 0.001$ ). Furthermore, their PVNT<sub>50</sub> were not significantly  
388 correlated with anti-s RBD level ( $\rho = 0.39$ ,  $p = 0.16$ ), alpha variant ( $\rho = 0.47$ ,  
389  $p = 0.076$ ) and delta variant ( $\rho = 0.26$ ,  $p = 0.35$ ) (Figure 8).

390 When considering the PVNT<sub>50 titers</sub>  $\geq 40$  (Nab positivity cut-off), we  
391 demonstrated that all participants ( $n = 15/15$ ) achieved PVNT<sub>50 titers</sub>  $> 40$  against  
392 wild type and Alpha variant. Participants ( $n = 13/15$ , 86.67%) had  
393 PVNT<sub>50 titers</sub>  $\geq 10$  against beta variant (Table 9).

394 Additionally, the correlation between PVNT<sub>50</sub> titer with PRNT<sub>50</sub> titer were wild  
395 type ( $\rho = 0.62$ ,  $p = 0.015$ ), alpha variant ( $\rho = 0.82$ ,  $p = 0.00022$ ), and Delta variant  
396 ( $\rho = 0.81$ ,  $p = 0.00044$ ) (Figure 9).

397

398

399

#### 400 **Adverse events following immunization**

##### 401 **Reactogenicity to first dose CoronaVac**

402 The reactogenicity population consisted of 155 individuals in the I/V group who  
403 got the second dosage of ChAdOx1 nCoV-19

404 The adverse events (AEs) to the first vaccine dose with CoronaVac in this study  
405 were described separately into two groups of samples. Group 1a was 30

406 participants from Bangsue Vaccination Center (BVC), who reported a higher  
407 rate of AEs from CoronaVac. Most AEs were mild and moderate symptoms  
408 such as immunization stress-related response (ISRR) (n=5, 16.67%), injected  
409 site pain (n=3, 10%), maculopapular rash (n=2, 6.67%), and others were  
410 described in Supplementary Table 2. Only 7 participants had severe AE  
411 included anaphylaxis (n=5, 16.67%), stroke (n=1, 3.33%) and  
412 central venous sinus thrombosis (n=1, 3.33%). Consequently, all participants in  
413 group 1a alter to receive the viral vector in the second dose due to the AE from  
414 the first vaccination (Table 2).

415 The group 1b were 125 participants from the MOPH vaccination center who  
416 received the I/V regimen based on the recommended vaccine schedule. This  
417 group has lower rates of reactogenicity from CoronaVac, the most common  
418 systemic reactions were feeling feverish (n=8, 6.4%), drowsiness (n=5, 4%),  
419 headache (n=2, 1.6%), and local AE such as injection site pain  
420 (n=1, 0.8%) (Table3).

421

#### 422 **Reactogenicity to second dose ChAdOx1 nCoV-19.**

423 After ChAdOx1 nCoV-19 as second vaccine, in total 155 participants, the most  
424 common systemic AEs were feeling feverish (n=104,67.10%), headache (n=51,32.9%),  
425 myalgia (n=40,25.81%), and malaise and drowsiness (n=30,19.35%). The most

426 common local responses such as injection site pain (n=54,35.06%) and other  
427 were described in Supplementary(Table4).

428

## 429 **Discussion**

430 The higher level of antibody response and neutralizing activity at 4 weeks  
431 against the Delta variant following the I/V schedule is encouraging for the  
432 national vaccine program implementation.

433 In our study, heterologous I/V vaccination with a mean 3.5-week interval  
434 presents antibody levels at 4 wks that are significantly higher than V/V, I/I, and  
435 natural infection 2021. This result could be explained from additional support  
436 from study<sup>14</sup>, the author demonstrated in mice that the first dose of inactivated  
437 viral vaccine followed by adenovirus vectors vaccine induced a significantly  
438 prominent T-cell response than two doses of inactivated vaccines. These might  
439 help B cell greater differentiation into plasma B cell that could provide  
440 higher antibody response to specific antigen more two doses of  
441 inactivated vaccines<sup>15</sup>.

442 In addition, antibody levels of the I/I schedule at 4 wks were lower than  
443 natural infection 2021. This agreement with a prior study that  
444 S1-RBD-binding IgG titer of natural infection 2021 was higher than  
445 homologous CoronaVac vaccination<sup>8</sup>.

446           Additionally, the I/V schedule provided a higher Nab level at  
447 2wks against Alpha variants than the Beta variant. This is compatible with a  
448 previous study utilizing a pseudovirus neutralization assay, serum from  
449 CoronaVac vaccinees collected 14 days following the second dose of the vaccine  
450 presented higher Beta resistance to neutralization than Alpha<sup>16</sup>. Moreover, this Nab  
451 level at 2wks against all VOCs decreased significantly compared to WT  
452 correlate with study<sup>8</sup>.

453           The Nab is highest to wild type variant, then to Alpha variant followed  
454 by delta variant, and the least Nab to Beta variant. This is consistent with a  
455 study that analyzed neutralization capacities by protein-based 206 ACE2 RBD  
456 competition assay was highest in wild-type, followed by alpha, delta, and Beta,  
457 respectively<sup>17</sup>.

458           Besides, participants in the I/V schedule resulted in high PRNT<sub>50</sub> and  
459 PVNT<sub>50</sub> titers against to delta variant. Immune protection against SARS-CoV-2  
460 infection symptoms are highly correlated with levels of neutralising  
461 antibodies<sup>18</sup>. The AstraZeneca vaccines were shown to be 60% effective against  
462 the Delta variant after two doses<sup>19</sup>.

463           This evidence provides supporting information for this I/V vaccination  
464 schedule in Thailand. Availability of immunogenicity data from the I/V  
465 vaccination schedule is vital for consideration of the national vaccination  
466 program to consider the best vaccine schedule that could stimulate the higher  
467 level of immunogenicity. Since the immunogenicity study may not be feasible

468 for every country, lower- and middle-income countries where inactivated viral  
469 vaccine and viral vector vaccine is available may use this evidence to support  
470 their decision to use alternative vaccination schedules. While multiple  
471 inactivated viral vaccines and viral vector vaccines are available, not all  
472 combinations of vaccine schedules produce satisfactory immunogenicity  
473 response, the early analysis in Thailand suggested that viral vector followed by  
474 inactivated viral vaccine-induced unsatisfactory immunogenicity<sup>20</sup>. While the  
475 correlation of protection for COVID19 vaccine has not been officially declared  
476 by World Health Organization, neutralizing activity to SARS-CoV-2 variants is  
477 likely related to the effectiveness of vaccination schedule<sup>21</sup>. Each country can  
478 measure the immunogenicity of these vaccination schedules in the target  
479 population and utilized this information to guide the vaccination schedules at  
480 the national level. In countries with CoronaVac and ChAdOx1 nCoV19 are  
481 available like Thailand, using this heterologous vaccination schedule is likely to  
482 enable the highest level of immunogenicity to Delta variants from these two  
483 vaccines.

484 An individual with a low level of immune response after COVID  
485 vaccination with this I/V schedule was diagnosed with HIV infection with a low  
486 level of CD4. Two sources of information are used to make a prediction and  
487 identify the possible problem. Infection with HIV, which causes immunological  
488 damage to B-cell compartments and antibody production, might be substantially  
489 reduced humoral response to antigens and insufficient response of persons

490 living with HIV to alternative vaccination, especially in those with low CD4 T-  
491 cell counts<sup>22</sup>. While immunogenicity is the proxy to the higher effectiveness, it  
492 is prudent to evaluate the safety and effectiveness of novel vaccine schedules  
493 after their introduction<sup>21</sup>. The introduction of the heterologous schedule of  
494 ChAdOx1 nCoV-19 followed by mRNA vaccination was evaluated for this  
495 vaccination schedule effectiveness (VE) in 100,000 fully vaccinated individuals,  
496 the real world VE of this vaccination schedule was at 88% (95% CI, 83-92)<sup>23</sup> .  
497 The large-scale evaluation of safety and effectiveness for the I/V schedule is  
498 still carried out in Thailand, the results of VE study should come out in the next  
499 month.

500 The adverse reactions to vaccination in this study were described  
501 separately from two groups (1a, 1b) of samples. Group 1a reported a higher rate  
502 of AEs from the first vaccination with the inactivated viral vaccine because this  
503 group received the viral vector due to the AEs from the first vaccination, the  
504 AEs rates from this group are not representative of AEs from the general  
505 population. Group 2b was retrieved from the general population that went to the  
506 vaccination center, the AEs from group 1b can be used as representative of  
507 general populations. The common AEs for the first vaccination with an  
508 inactivated viral vector was feeling feverish (n = 8, 6.4 %). According to our  
509 initial findings, the AEs after the second dose of ChAdOx1 nCoV-19 in the I/V  
510 schedule were well tolerated and generally safe. The adverse event



511 profile reported here is comparable to previously reported adverse events  
512 following vaccination with ChAdOx1 nCoV-19<sup>24</sup>. Most participants had mild or  
513 moderate adverse effects and no report of serious AEs. The severity of local and  
514 systemic AEs of I/V schedule after the second dose of ChAdOx1 nCoV-19 in 7  
515 days was mild to moderate corresponded to the reported AEs in phase II and  
516 phase III study of ChAdOx1 nCoV-19 (UK, Brazil, South Africa)<sup>25</sup>. The rate of  
517 systemic AEs, such as fever, recorded after the second dosage of ChAdOx1  
518 nCoV-19 was higher (67.1%) than the earlier study (51%)<sup>26</sup>. However, Both  
519 systemic AEs (such as headache, malaise, myalgia) and local AE (such as  
520 injection site pain) were lower rates than this study<sup>26</sup>. This higher level of  
521 immunogenicity and the acceptable level of adverse reactions profile of  
522 this I/V vaccination schedule, this vaccination schedule is likely a better  
523 solution for countries that had access to both Inactivated whole virus vaccine  
524 and viral vector vaccine-like Thailand. The questions that remained to be  
525 answered are the duration of immunogenicity which may need following up  
526 study at 3 months, 6 months, 9 months, and 1 year. The decreasing levels of  
527 antibody level at 2 weeks to 4 weeks suggested that immunogenicity level may  
528 last between 3 to 6 months and the temporal relationship of effectiveness should  
529 be monitored carefully by the national vaccination program. The third dose is  
530 likely necessary for boosting immunogenicity after the I/V vaccine schedule and

531 the types and timing of vaccine should be determined as the follow-up study  
532 from this cohort of vaccine recipients for providing a further recommendation.

533         There are several limitations to our research. First, our study did not  
534 collect comparison data on immunity levels at baseline before the study and  
535 after the first vaccine dose, hence, we could not exclude the effect of the  
536 previous infection on immunogenicity. However, the COVID-19 infection rate  
537 in Thailand was low before July 2021, there is a small possibility to include  
538 previously infected COVID-19 cases but these individuals should not affect the  
539 immunogenicity results in this study due to the immunity induced by infection  
540 were much higher in previously infected individuals compared with single-dose  
541 vaccination. A larger sample size is needed to detect uncommon adverse events  
542 such as vaccine-induced thrombotic thrombocytopenia and further studies  
543 should be done at the time of implementation of this vaccine schedule in the  
544 national vaccine program. Moreover, the PRNT<sub>50</sub> and PVNT<sub>50</sub> were assessed  
545 only in I/V regimen, limiting the comparability of the I/V regimen with other  
546 vaccine schedules, also the limited time for this study resulted in a smaller  
547 sample size that had neutralizing activities, however, the high level of  
548 neutralizing antibody suggested that the number of sample size is sufficient for  
549 the conclusion that I/V schedule is better than I/I schedule and comparable to  
550 V/V schedule.

551         Finally, our research offers crucial real-world proof of the safety and  
552 immunogenicity of heterologous CoronaVac- ChAdOx1 nCoV-19

553 immunization. The I/V vaccination is a mixed regimen that induced higher  
554 immunogenicity with a shorter duration to peak immunogenicity compared to  
555 the I/I schedule. In a situation where the viral vector vaccine is inadequate, we  
556 should consider this vaccine schedule for responding to Delta Variants. We  
557 propose that this initial assessment encourage future research of heterologous  
558 prime-boost vaccination regimens for COVID-19.

559

## 560 **Ethics Statement**

561 The ethical approval of this study was approved by the ethical committee of the  
562 Department of Medical Sciences with approval number; MOPH 0625/EC060

## 563 **Conflicts of interest**

564 All authors declare no conflict of interest.

## 565 **Funding**

566 Department of Medical Sciences provided funding for this project. Studies, data  
567 collection, analysis, and interpretation, as well as manuscript preparation and  
568 the determination to submit the paper for publication, were all independent of  
569 funding sources.

## 570 **Acknowledgments**

571 We would like to express our gratitude to the whole COVID-19 research team  
572 including all of the study participants. We thank Dr. Mark Simmerman for his  
573 critical data and recommendations.

574

575

576

577

## 578 References

- 579 1. Effectiveness of an Inactivated SARS-CoV-2 Vaccine.  
580 <https://doi.org/10.1056/NEJMc2112423> (2021) doi:10.1056/NEJMc2112423.
- 581 2. Bernal, J. L. *et al.* Effectiveness of COVID-19 vaccines against the B.1.617.2 variant.  
582 *medRxiv* 2021.05.22.21257658 (2021) doi:10.1101/2021.05.22.21257658.
- 583 3. Lu, S. Heterologous Prime-Boost Vaccination. *Current opinion in immunology* **21**, 346  
584 (2009).
- 585 4. Logunov, D. Y. *et al.* Safety and immunogenicity of an rAd26 and rAd5 vector-based  
586 heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-  
587 randomised phase 1/2 studies from Russia. *The Lancet* **396**, 887–897 (2020).
- 588 5. Abhishek Anand, Justin Sandefur, Arvind Subramanian write: Why we need to count  
589 the Covid dead. [https://indianexpress.com/article/opinion/columns/india-covid-deaths-](https://indianexpress.com/article/opinion/columns/india-covid-deaths-second-wave-7412619/)  
590 [second-wave-7412619/](https://indianexpress.com/article/opinion/columns/india-covid-deaths-second-wave-7412619/).
- 591 6. Dyer, O. Covid-19: Indonesia becomes Asia's new pandemic epicentre as delta variant  
592 spreads. *BMJ* **374**, n1815 (2021).
- 593 7. Chen, N. *et al.* Epidemiological and clinical characteristics of 99 cases of 2019 novel  
594 coronavirus pneumonia in Wuhan, China: a descriptive study. *The Lancet* **395**, 507–  
595 513 (2020).
- 596 8. Vacharathit, V. *et al.* SARS-CoV-2 variants of concern exhibit reduced sensitivity to  
597 live-virus neutralization in sera from CoronaVac vaccinees and naturally infected  
598 COVID-19 patients. *medRxiv* 2021.07.10.21260232 (2021)  
599 doi:10.1101/2021.07.10.21260232.
- 600 9. Yorsaeng, R. *et al.* Immune response elicited from heterologous SARS-CoV-2  
601 vaccination: Sinovac (CoronaVac) followed by AstraZeneca (Vaxzevria). *medRxiv*  
602 2021.09.01.21262955 (2021) doi:10.1101/2021.09.01.21262955.
- 603 10. di Genova, C. *et al.* Production, titration, neutralisation and storage of SARS-CoV-2  
604 lentiviral pseudotypes (preprint). *Methods and Protocols preprint server* (2020)  
605 doi:10.6084/M9.FIGSHARE.13502580.V2.
- 606 11. R: The R Project for Statistical Computing. <https://www.r-project.org/>.
- 607 12. RStudio - RStudio. <https://www.rstudio.com/products/rstudio/>.

- 608 13. Alboukadel Kassambara. rstatix: Pipe-Friendly Framework for Basic Statistical Tests.  
609 R package version 0.7.0. <https://cran.r-project.org/package=rstatix> (2021).
- 610 14. Zhang, J. *et al.* Boosting with heterologous vaccines effectively improves protective  
611 immune responses of the inactivated SARS-CoV-2 vaccine.  
612 <https://doi.org/10.1080/22221751.2021.1957401> 1–28 (2021)  
613 doi:10.1080/22221751.2021.1957401.
- 614 15. Takemori, T., Tarlinton, D., Hiepe, F. & Andreas, R. B Cell Memory and Plasma Cell  
615 Development. *Molecular Biology of B Cells: Second Edition* 227–249 (2015)  
616 doi:10.1016/B978-0-12-397933-9.00014-X.
- 617 16. GL, W. *et al.* Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization.  
618 *The New England journal of medicine* **384**, 2354–2356 (2021).
- 619 17. Junker, D. *et al.* Reduced serum neutralization capacity against SARS-CoV-2 variants  
620 in a multiplex ACE2 RBD competition assay. *medRxiv* 2021.08.20.21262328 (2021)  
621 doi:10.1101/2021.08.20.21262328.
- 622 18. Khoury, D. S. *et al.* Neutralizing antibody levels are highly predictive of immune  
623 protection from symptomatic SARS-CoV-2 infection. *Nature Medicine* 2021 **27**:7 **27**,  
624 1205–1211 (2021).
- 625 19. Bernal, J. L. *et al.* Effectiveness of COVID-19 vaccines against the B.1.617.2 variant.  
626 *medRxiv* 2021.05.22.21257658 (2021) doi:10.1101/2021.05.22.21257658.
- 627 20. Wanlapakorn, N. *et al.* Immunogenicity of heterologous prime/booster-inactivated and  
628 adenoviral-vectored COVID-19 vaccine: real-world data. (2021)  
629 doi:10.21203/RS.3.RS-785693/V2.
- 630 21. Earle, K. A. *et al.* Evidence for antibody as a protective correlate for COVID-19  
631 vaccines. *medRxiv* 2021.03.17.20200246 (2021) doi:10.1101/2021.03.17.20200246.
- 632 22. Ambrosioni, J. *et al.* Overview of SARS-CoV-2 infection in adults living with HIV.  
633 *The Lancet HIV* **8**, e294–e305 (2021).
- 634 23. Gram, M. A. *et al.* Vaccine effectiveness when combining the ChAdOx1 vaccine as  
635 the first dose with an mRNA COVID-19 vaccine as the second dose. *medRxiv*  
636 2021.07.26.21261130 (2021) doi:10.1101/2021.07.26.21261130.
- 637 24. Folegatti, P. M. *et al.* Safety and immunogenicity of a candidate Middle East  
638 respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-  
639 label, non-randomised, uncontrolled, phase 1 trial. *The Lancet Infectious Diseases* **20**,  
640 816–826 (2020).
- 641 25. Ramasamy, M. N. *et al.* Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine  
642 administered in a prime-boost regimen in young and old adults (COV002): a single-  
643 blind, randomised, controlled, phase 2/3 trial. *The Lancet* **396**, 1979–1993 (2020).
- 644 26. Folegatti, P. M. *et al.* Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine  
645 against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised  
646 controlled trial. *The Lancet* **396**, 467–478 (2020).

